A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Demand GLP-1 Medications as Prescription Drug Market Grows SCHAUMBURG, IL / ACCESS Newswire / February 20, 2025 / Giftify, Inc. (NASDAQ:GIFT) (the "Company"), the owner and operator of CardCash.com ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...

The participants were divided into two groups, with half receiving weekly low-dose injections of semaglutide (Ozempic and Wegovy), a GLP-1 agonist, and the other half getting a placebo shot.